Framatome and IBA to partner to develop an Astatine-211 CyclotronNetwork in Europe and the USA

Framatome and IBA to partner to develop an Astatine-211 CyclotronNetwork in Europe and the USA
SHARE

25 – Framatome, an international leader in nuclear energy committed to developing products and services for the healthcare industry, and IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today announced they have signed a Memorandum Of Understanding to start a strategic partnership aimed at advancing industrial-scale production of Astatine-211 (211At), an alpha-emitting radioisotope across Europe and the United States.

See More

Registrations for the First Noar Europe annual meeting will open on Monday, June 2 via the EventBrite platform.
3th GLOBAL MEETING WG & Core Group meeting of the COST Action CA19114 Network for Optimized Astatine Labeled Radiopharmaceuticals minutes:
This international Meeting, fully dedicated to astatine-211, aims to convene actors from around the world while emphasizing sustainable practices. These three days will offer a comprehensive overview of the accomplishments made over the past...